Teva Pharmaceutical Industries Ltd Stock Price Today (NSE: IL&FSTRANS)
Fundamental Score
Teva Pharmaceutical Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Teva Pharmaceutical Industries Ltd share price today is ₹2.32, down 1.28% on NSE/BSE as of 8 June 2026. Teva Pharmaceutical Industries Ltd (IL&FSTRANS) is a Small-cap company in the Civil Construction sector with a market capitalisation of ₹93.05 (Cr). The 52-week high for IL&FSTRANS share price is ₹4.40 and the 52-week low is ₹1.75.
Teva Pharmaceutical Industries Ltd Share Price Chart — NSE/BSE Historical Performance
Teva Pharmaceutical Industries Ltd share price chart: -6.97% return over the past month. 52-week high ₹4.40, 52-week low ₹1.75.
Teva Pharmaceutical Industries Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2.35 | ₹2.39 | ₹2.30 | ₹2.31 | 28.62K (Cr) | |
| ₹2.30 | ₹2.36 | ₹2.23 | ₹2.32 | 33.38K (Cr) | |
| ₹2.26 | ₹2.31 | ₹2.16 | ₹2.25 | 43.72K (Cr) | |
| ₹2.30 | ₹2.43 | ₹2.22 | ₹2.27 | 48.06K (Cr) | |
| ₹2.34 | ₹2.37 | ₹2.30 | ₹2.33 | 23.51K (Cr) | |
| ₹2.26 | ₹2.36 | ₹2.26 | ₹2.34 | 29.71K (Cr) | |
| ₹2.45 | ₹2.45 | ₹2.30 | ₹2.31 | 39.59K (Cr) | |
| ₹2.35 | ₹2.48 | ₹2.32 | ₹2.40 | 54.60K (Cr) | |
| ₹2.31 | ₹2.39 | ₹2.25 | ₹2.37 | 51.84K (Cr) | |
| ₹2.32 | ₹2.32 | ₹2.25 | ₹2.29 | 10.00K (Cr) |
Teva Pharmaceutical Industries Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2.30 | ₹2.39 | ₹2.23 | ₹2.31 | +0.43% | |
| ₹2.38 | ₹2.68 | ₹2.16 | ₹2.25 | -5.46% | |
| ₹1.84 | ₹2.76 | ₹1.75 | ₹2.34 | +27.17% | |
| ₹2.48 | ₹2.48 | ₹1.84 | ₹1.84 | -25.81% | |
| ₹2.74 | ₹2.94 | ₹2.42 | ₹2.45 | -10.58% | |
| ₹3.00 | ₹3.04 | ₹2.54 | ₹2.73 | -9.00% | |
| ₹2.99 | ₹3.12 | ₹2.42 | ₹2.90 | -3.01% | |
| ₹3.18 | ₹3.18 | ₹2.73 | ₹2.95 | -7.23% | |
| ₹3.14 | ₹3.25 | ₹2.88 | ₹3.03 | -3.50% | |
| ₹3.10 | ₹3.34 | ₹2.93 | ₹3.06 | -1.29% | |
| ₹3.32 | ₹3.46 | ₹2.84 | ₹3.19 | -3.92% | |
| ₹4.15 | ₹4.40 | ₹3.06 | ₹3.32 | -20.00% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Teva Pharmaceutical Industries Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Teva Pharmaceutical Industries Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of IL&FSTRANS across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Cash Generation (₹847.07 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (73.22%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
8 factors identified
Suboptimal ROCE (-18.13%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.29%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-1100.85%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-51.00% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-10.02x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.42%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (98.23%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Teva Pharmaceutical Industries Ltd vs Civil Construction Peers
Peer Comparison - Civil Construction
Compare Teva Pharmaceutical Industries Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Teva Pharmaceutical Industries LtdTeva Pharmaceut...Selected✓ IL&FSTRANS • 533177 | 0/100 | ₹2.32₹2 | ₹93.05₹93.05 | — — | — — | -18.13%Poor -18.13% Poor | — — | — — | -51.00%Poor -51.00% Poor | 0.00% |
Larsen & Toubro LtdLarsen & Toubro... LT • 500510 | 35.9/100 | ₹3988.50₹3989 | ₹560453.09₹560453.09 | 34.87Average 34.9 Average | 16.55%Good 16.55% Good | 14.49%Average 14.49% Average | 1.32Average 1.3 Average | 9.73%Good 9.73% Good | 11.95%Good 11.95% Good | 0.83% |
Rail Vikas Nigam LtdRail Vikas Niga... RVNL • 542649 | 34.9/100 | ₹239.19₹239 | ₹67085.37₹67085.37 | 59.08Average 59.1 Average | 14.01%Average 14.01% Average | 14.72%Average 14.72% Average | 0.52Good 0.5 Good | 11.11%Good 11.11% Good | 6.52%Good 6.52% Good | 0.53% |
Nbcc India LtdNbcc India Ltd... NBCC • 534309 | 60.3/100 | ₹103.70₹104 | ₹31859.97₹31859.97 | 47.71Average 47.7 Average | 25.54%Excellent 25.54% Excellent | 33.17%Excellent 33.17% Excellent | 0.00Excellent 0.0 Excellent | 51.02%Excellent 51.02% Excellent | 8.28%Good 8.28% Good | 0.57% |
24.4/100 | ₹21.66₹22 | ₹26046.27₹26046.27 | 29.75Average 29.8 Average | 5.91%Poor 5.91% Poor | 7.82%Poor 7.82% Poor | 1.02Average 1.0 Average | 7.82%Good 7.82% Good | 2.13%Average 2.13% Average | 0.70% | |
29.9/100 | ₹1290.20₹1290 | ₹20171.65₹20171.65 | 24.57Average 24.6 Average | 9.96%Poor 9.96% Poor | 15.95%Good 15.95% Good | 0.69Good 0.7 Good | 8.45%Good 8.45% Good | 11.98%Good 11.98% Good | 0.76% | |
Kec International LtdKec Internation... KEC • 532714 | 48.5/100 | ₹496.65₹497 | ₹18483.64₹18483.64 | 27.06Average 27.1 Average | 12.02%Average 12.02% Average | 17.98%Good 17.98% Good | 0.94Good 0.9 Good | 0.06%Average 0.06% Average | 12.80%Good 12.80% Good | 0.79% |
Afcons Infrastructure LtdAfcons Infrastr... AFCONS • 544280 | 14.1/100 | ₹326.20₹326 | ₹15033.09₹15033.09 | 29.93Average 29.9 Average | 11.06%Average 11.06% Average | 19.59%Good 19.59% Good | 0.66Good 0.7 Good | 14.18%Good 14.18% Good | 4.78%Average 4.78% Average | 0.61% |
Ircon International LtdIrcon Internati... IRCON • 541956 | 30.2/100 | ₹135.14₹135 | ₹14995.61₹14995.61 | 24.97Average 25.0 Average | 11.33%Average 11.33% Average | 11.60%Average 11.60% Average | 0.80Good 0.8 Good | 8.27%Good 8.27% Good | 14.82%Good 14.82% Good | 1.66% |
ITD Cementation India LtdITD Cementation... CEMPRO • 509496 | 60.7/100 | ₹1046.80₹1047 | ₹14797.54₹14797.54 | 33.22Average 33.2 Average | 21.78%Excellent 21.78% Excellent | 27.64%Excellent 27.64% Excellent | 0.48Excellent 0.5 Excellent | 37.51%Excellent 37.51% Excellent | 26.03%Excellent 26.03% Excellent | 0.23% |
Techno Electric & Engineering Co LtdTechno Electric... TECHNOE • 542141 | 66.3/100 | ₹1072.30₹1072 | ₹13872.92₹13872.92 | 31.14Average 31.1 Average | 12.81%Average 12.81% Average | 16.54%Good 16.54% Good | 0.02Excellent 0.0 Excellent | 18.85%Excellent 18.85% Excellent | 21.09%Excellent 21.09% Excellent | 0.75% |
Top Civil Construction Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Larsen & Toubro Ltd share price560453.09 Cr
- Rail Vikas Nigam Ltd share price67085.37 Cr
- Nbcc India Ltd share price31859.97 Cr
- IRB Infrastructure Developers Ltd share price26046.27 Cr
- Kalpataru Projects International Limited share price20171.65 Cr
Teva Pharmaceutical Industries Ltd Quarterly Performance
Latest quarterly metrics for IL&FSTRANS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.66%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-1100.85%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-51.00%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Teva Pharmaceutical Industries Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for IL&FSTRANS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Teva Pharmaceutical Industries Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Teva Pharmaceutical Industries Ltd (IL&FSTRANS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Teva Pharmaceutical Industries Ltd
About IL&FSTRANS (Teva Pharmaceutical Industries Ltd)
Teva Pharmaceutical Industries Ltd is a global pharmaceutical titan, renowned for its extensive portfolio of generic and specialty medicines. With a presence spanning continents, T...eva operates a vast network of manufacturing facilities and research and development centers dedicated to producing affordable and accessible healthcare solutions. From complex generics that challenge the status quo to innovative branded therapies addressing critical medical needs, Teva strives to improve patient outcomes worldwide. Their commitment to quality and compliance is paramount, ensuring that every product meets the highest standards of safety and efficacy. This global footprint demands a strong operational backbone, including robust supply chains and logistical networks that allow for the timely distribution of medications to healthcare providers and patients. IL&FSTRANS, a key player in civil construction, focuses on building and maintaining vital transport networks. Imagine a tapestry of asphalt stretching across vast landscapes, connecting bustling urban centers and remote rural communities – that is the work of IL&FSTRANS. They engineer and oversee the development of highways that hum with the passage of commerce, soaring flyovers that untangle congested city streets, and sturdy bridges that span formidable rivers. Beyond concrete and steel, they contribute to the very arteries of movement that enable economic growth and social connection. The company's commitment extends to the ongoing care of these vital routes, providing essential maintenance and toll collection services to ensure their long-term viability and efficiency. IL&FSTRANS are not just builders; they are caretakers of infrastructure, responsible for keeping transportation flowing smoothly. From the initial blueprint to the final coat of paint, they manage every aspect of these intricate projects, ensuring that each structure meets stringent safety standards and environmental regulations. Their expertise extends beyond traditional roadwork to include modern transit systems like metro rail projects and efficient city bus networks. With a commitment to sustainable practices, they incorporate innovative design and materials to minimize environmental impact. Ultimately, their work empowers the efficient movement of people and goods, fostering progress and connectivity across communities and regions.
Company Details
Key Leadership
Corporate Events
Latest News
IL&FSTRANS Share Price: Frequently Asked Questions
What is the current share price of Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd (IL&FSTRANS) trades at ₹2.32 on NSE and BSE. Market cap ₹93.05 (Cr). Educational data only.
What is the P/E ratio of Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd has a P/E of N/Ax vs industry average 18.93x.
What is the Bull Run score for Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Teva Pharmaceutical Industries Ltd pay dividends?
Teva Pharmaceutical Industries Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd has debt-to-equity of N/A.
Is Teva Pharmaceutical Industries Ltd a good investment?
Bull Run gives Teva Pharmaceutical Industries Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.